Trillium Therapeutics Inc. announced that Eric L. Sievers, M.D., has assumed the position of Chief Medical Officer. In this role, he will lead the company in
evaluating and implementing clinical development strategies for advancement and
approval of its clinical programs, with initial emphasis on the company's CD47 program.
Dr. Sievers brings more than 25 years' experience in the biotechnology industry and academia.